Aviragen Antiviral Drug Vapendavir Fails Phase IIb Study in Asthma Patients

Aviragen Therapeutics reported its second Phase II trial disappointment in as many weeks. The firm said that the Phase IIb SPIRITUS study evaluating the oral capsid-binding antiviral drug, vapendavir, in asthma patients with rhinovirus (RV) infection, failed to meet its primary endpoint. At the start of this month Aviragen reported on topline Phase IIa data indicating that a second clinical candidate, BTA585, failed to reduce viral load in adults challenged intranasally with syncytial virus (RSV